All In MedTech

Device Trial Radar · NCT07291739

A Clinical Evaluation of a Phakic Intraocular Lens

Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Aug 22, 2022

Primary completion

Oct 18, 2024

Study completion Oct 18, 2024

Sponsor

Lead sponsor
Staar Surgical CompanyNot on our public-company list
Sponsor type
Industry
First posted
Dec 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens with Aspheric (EDOF) Optic as refractive elements to correct or reduce myopia or hyperopia with presbyopia with or without astigmatism.

Conditions

  • Myopia
  • Hyperopia
  • Astigmatism
  • Presbyopia

Interventions

  • Implantable Collamer Lens (ICL)Device

    EVO+ Visian Implantable Collamer Lens with Aspheric (EDOF) Optic models VTICM6/VTICH6 (TEDOF ICL) and VICM6/VICH6 (EDOF ICL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in visual acuityTime frame: 1 month, 3 months and 6 months postoperatively
  2. Change in refractive cylinderTime frame: 1 month, 3 months and 6 months postoperatively
  3. Lens axis misalignmentTime frame: 1 month, 3 months and 6 months postoperatively

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asian Eye Institute

    Makati City, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.